Celldex Therapeutics’ $287.5 Million Common Stock Offering

Lowenstein Sandler represented Celldex Therapeutics in the offering.

Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) executed its $287.5 million public offering of common stock.

Jefferies, SVB Leerink, Guggenheim Securities, and Cantor Fitzgerald acted as joint book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers for the offering.

Celldex is a clinical-stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

The Lowenstein team was led by Anthony O. Pergola (Picture) and Kate Basmagian and included Michael J. Lerner, Robert J. Paradiso, and Kaitlyn M. Baietto.

Involved fees earner: Kaitlyn Baietto – Lowenstein Sandler; Kate Basmagian – Lowenstein Sandler; Michael Lerner – Lowenstein Sandler; Robert Paradiso – Lowenstein Sandler; Anthony Pergola – Lowenstein Sandler;

Law Firms: Lowenstein Sandler;

Clients: Celldex Therapeutics;

Martina Bellini

Author: Martina Bellini